Trial Profile
A Randomized Trial to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa-Part A: A Randomized Trial of Ring Vaccination to Evaluate Ebola Vaccine Efficacy and Safety in Guinea, West Africa. Part B- Safety and immunogenicity of VSV¿G/ZEBOV-GP among Frontline Workers
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 12 Oct 2022
Price :
$35
*
At a glance
- Drugs RVSV-S-GP/VP40 vaccine (Primary)
- Indications Ebola virus infections
- Focus Registrational; Therapeutic Use
- 05 Oct 2022 Results of post-hoc pooled analysis of 3 studies(PREVAIL:NCT02344407; FLW: PACTR201503001057193; STRIVE:NCT02378753) published in the Vaccine
- 25 Oct 2020 Results of post-hoc pooled analysis of 3 studies (Guinea (FLW), Sierra Leone (STRIVE), and Liberia (PREVAIL)), presented at the IDWeek 2020.
- 19 Dec 2019 According to a Food and Drug Administration media release, the Food and Drug Administration (FDA) has approved Ervebo, a vaccine for the prevention of Ebola virus disease (EVD), caused by Zaire ebolavirus in individuals 18 years of age and older.The approval of Ervebo is supported by this study conducted in Guinea during the 2014-2016 outbreak in individuals 18 years of age and older.